2019 preliminary results · over 850 systems sold into over 500 medical institutions • revenue...
TRANSCRIPT
2019 Preliminary Results
Transforming ultrasound scanning through AI
Year ended 31 December 2019 (unaudited)
• Revenue up 11% to £5.9m
• Gross margin strong at 58%
• Close to divisional EBITDA breakeven
• North America revenue up 53% to £2.7m
• SonoSite co-marketing agreement signed
SIMULATION BASED TRAINING IN THE CLASSROOM AI BASED IMAGE ANALYSIS IN THE CLINIC
Providing a range of hi-fidelity simulators for educating and training ultrasound practitioners and improving patient care by raising scanning standards around the world
Developing a range of AI-based software for real-time guidance and image analysis during ultrasound scanning,
to improve the speed and standard of scanning worldwide
SIMULATION DIVISION CLINICAL AI DIVISION
• First OEM contract signed
• All milestones on target
• Second product at regulatory phase
and in commercial discussions
• Image database grown to 4m images
HIGHLIGHTS OF THE YEAR
3
SIMULATION DIVISION
Training to the highest standards
Over 850 systems sold into over 500 medical institutions
• Revenue steady at £2.6m• Important multiple sales to
Romanian universities• Encouraging sales in Iberia
ROW:
Simulation Division
North America:
• Revenue up 53% to £2.7m• Strong BodyWorks and HeartWorks
sales• SonoSite agreement signed• Support team expanded
UK:
• Revenue down 27% to £0.7m• Difficult purchasing market despite clinical demand• Q1 2020 showing encouraging early recovery
Simulation division revenue growth since 2013
United Kingdom19%
North America32%
Rest of World49%
Geographic Revenue
2018
United Kingdom
11%
North America45%
Rest of World44% Geographic
Revenue2019
2013 2014 2015 2016 2017 2018 2019
H2 0.7 1.1 1.2 2.0 2.1 2.8 2.6
H1 0.6 0.7 1.1 1.3 2.1 2.5 3.3
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
Simulation Division Revenue
H1 H2
£5.3m
£4.2m
£3.3m
£2.3m
£1.8m
£1.3m
£5.9m
12%
44%
BodyWorks for COVID-19
6
• Post year end launch
• New version of BodyWork’s PoCUS simulator
released for COVID-19
• Enables hands-on training for frontline
clinical staff to use lung ultrasound to
diagnose COVID-19 disease
• Free upgrade for all hospital users
• First systems in the UK and US live on 23
March 2020
CLINICAL AI DIVISION
Speeding up scanning and reducing misdiagnosis
• First long-term licensing agreement
• with one of the world’s leading ultrasound
manufacturers
• Integrating our AI image analysis
software
• onto a global range of ultrasound systems
• Generating high margin royalty
• Revenues expected from 2021
• Following regulatory approval
• More agreements expected to follow
First global AI licence signed
9
Proof of Concept
OEM agreement
OEM integration
First revenue expected
Product in development
Regulatory process
ProductAI
PLATFORM
Image analysis product 1
Image analysis product 4
H1 2021
H1 2022
2021
TBC
TBC
TBC
TBC
TBC
TBC
TBC
TBC
TBC
AI software platform A
Image analysis product 6
Image analysis product 9
Image analysis product 2
Image analysis product 5
Image analysis product 7
Image analysis product 3
AI software platform B
AI software platform C
AI software platform D
Image analysis product 4
Image analysis product 6
Image analysis product 9
Multi-platform, multi-licence strategy
10
Launch
Image analysis product 4
OEM version
Non OEM version
COVID-19 Impact
• The recent spread of the COVID-19 virus is impacting all regions in which the Group
operates
• There is also considerable uncertainty over the likely duration of the disruption
• To counter any short term slow-down in global simulator sales, we have implemented
several cost-saving measures
• This will enable the Group’s EBITDA in FY2020 to remain in line with expectations
• The outlook for the medium and long term remains unchanged
• Group expects to have sufficient funds to continue its simulation and AI business activities
for 12 months
• When the revenues from its first AI software licence agreement are expected to come on
stream
11
FINANCIALS2019 UNAUDITED PRELIMINARY RESULTS
CONSOLIDATED INCOME STATEMENT
13
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
14
CONSOLIDATED STATEMENT OF CASH FLOWS
15